相小強:個人經歷,研究方向,學術成果,學術兼職,所獲獎勵,科研項目,發表論文,著作

相小強，復旦大學藥學院副研究員、博士生導師，臨床藥理學博士，現任臨床藥學與藥事管理系主任，上海市定量藥理學專業技術平台PI。主要研究方向為定量藥理學及生理藥代動力學（PBPK）模型開發，聚焦藥物相互作用研究和兒科藥物開發領域。

1999年獲北京大學藥學學士學位，2002年、2006年分獲上海醫藥工業研究院藥劑學碩士、新加坡國立大學藥學碩士學位，2012年獲赫爾辛基大學博士學位。2005年至2007年在新加坡國立癌症中心從事藥物代謝酶與轉運體遺傳藥理學研究，2007年參與新加坡CombinatoRx公司新藥研發工作。2012年起任教復旦大學藥學院，主持國家自然科學基金項目3項及省部級基金5項，主編英文專著《Pharmacogenomics in Precision Medicine》，發表SCI論文82篇，獲國家專利授權2項、軟體著作權5項。擔任中國藥理學會定量藥理專業委員會常務委員等學術職務。

基本介紹

中文名：相小強
國籍：中國
學位/學歷：博士
職業：教師
專業方向：藥物基因組學、生理藥代動力學建模和藥物相互作用
就職院校：復旦大學藥學院

個人經歷,研究方向,學術成果,學術兼職,所獲獎勵,科研項目,發表論文,著作教材,發明專利,

個人經歷

1999年畢業於北京大學藥學本科，2002年獲上海醫藥工業研究院藥劑學碩士，2006年獲新加坡國立大學藥學碩士，2012年獲赫爾辛基大學臨床藥理學博士。2005年~2007年在新加坡國立癌症中心任臨床研究助理，從事藥物代謝酶和轉運體的遺傳藥理學研究以及臨床藥代動力學研究。2007年在新加坡CombinatoRx公司從事新藥開發中的藥代動力學，藥物相互作用，生物分析和抗病毒藥物的體內藥效評價等研究。2012年8月作為引進人才進入復旦大學藥學院臨床藥學與藥事管理教研室工作。教授，博士生導師，臨床藥理學博士。復旦大學藥學院臨床藥學與藥事管理系主任，上海市定量藥理學專業技術服務平台負責人。主持各類縱向科研項目12項，其中國家自然科學基金項目3項，省部級基金項目5項，校院級基金項目4項。發表SCI論文82篇和中文核心期刊論文22篇，已授權國家專利2項和軟體著作權5項，主編英文專著1本，副主編中文專著1本，參編中英文專著和教材4本。擔任《藥學學報》、《藥物不良反應雜誌》、《中國臨床藥學雜誌》雜誌編委。參與編寫多項CDE指導原則和中國專家共識。

研究方向

遺傳藥理學，藥物轉運體，藥物代謝動力學，藥物相互作用，和個體化給藥。

學術成果

主持國家自然科學基金面上項目和Helsinki Biomedicum基金各一項，發表10篇SCI論文，已授權國家專利一項。

學術兼職

（1）中國藥理學會定量藥理專業委員會常務委員

（2）中國藥理學會藥物代謝專業委員會委員

（3）中國藥理學會表觀遺傳藥理專業委員會委員

（4）中國藥理學會治療藥物監測研究專業委員會定量藥理學組委員

（5）中國藥學會中醫腫瘤藥物與臨床研究專業委員會委員

（6）上海藥理學會藥物代謝專業委員會副主任委員

（7）上海藥理學會臨床藥理專業委員會委員

（8）《藥學學報》中英文刊編委

（9）《藥物不良反應雜誌》編委

（10）《中國臨床藥學雜誌》編委

（11）上海藥學會監事

所獲獎勵

（1）2020年度一健康基金優秀教師常規獎三等獎

（2）2019年度“復旦大學第一三共製藥獎教金”

（3）上海醫學院課程思政教案大賽一等獎

（4）復旦大學2017年教學成果一等獎：“臨床藥學人才培養模式的探索與創新”

（5）復旦大學藥學院2017屆畢業生“我心目中的好老師”

（6）2014年度藥學院青年教師講課比賽二等獎

科研項目

1.國家自然科學基金面上項目，82373952，項目名稱：基於定量系統藥理學模型和類器官的人促卵泡激素精準用藥研究，2024-2027，主持。

2.上海市2023年度“科技創新行動計畫”專業技術服務平台，項目名稱：上海市定量藥理學專業技術服務平台，2023-2025，主持

3.國家自然科學基金國際(地區)合作與交流項目，82011540409，題目：基於PBPK模型和IVIVE研究安羅替尼合用P450色素酶促變藥時的藥物相互作用和給藥策略，2020-2022，主持。

4.國家自然科學基金面上項目，81473409，項目名稱：PBPK建模預測CYP3A5基因型對五酯膠囊和他克莫司藥動相互作用的影響，2015-2018，主持。

5.2023年度上海市法醫學重點實驗室暨法務部司法鑑定重點實驗室開放課題，KF202304，項目名稱：基於生理藥動學模型和分子建模的U-47700 和苯二氮卓類藥物的協同作用機制研究，2023-2025，主持。

6.上海市2018年度“科技創新行動計畫”實驗動物研究領域項目，18140900900，項目名稱：生理藥動學模型結合體外動態Bio-PK/PD系統替代大鼠進行藥代動力學研究，2018-2021，主持。

7.2022年度上海市衛生健康委員會衛生行業臨床研究專項面上項目，202240116，項目名稱：基於PBPK模型的比馬前列素眼瞼給藥研究，2023-2025,主持。

8.2018年度上海市衛生行業臨床研究專項面上項目，項目名稱：201840057，基於代謝轉運通路和Bio-PK/PD系統研究丙基硫氧嘧啶所致肝損傷的機制，2019-2021，主持。

9.The University of Sydney-Fudan University Partnership Collaboration Awards (PCA)2019 round, 項目名稱：3D printed microneedle patches for personalized medicine，2019-2020，主持。

10. 復旦大學附屬浦東醫院-復旦大學藥學院融和基金項目，RHJJ2017-05，項目名稱：基於生理藥動學模型的口黏膜劑的生物等效性豁免研究，2018-2019，主持。

11. 復旦大學附屬中山醫院閔行分院-復旦大學藥學院戰略合作自主研究課題融合基金，RO-MY201710，項目名稱：基於生理藥動學模型研究阿托伐他汀和伏立康唑的精準聯合用藥，2018-2019，主持。

12. 2010年芬蘭赫爾辛基Biomedicum Helsinki Foundation, 項目名稱：Effects of genetic polymorphisms in SLCO1B1 and CYP7A1 on plasma bile acids in humans and the pharmacokinetics of therapeutic ursodeoxycholic acid”，主持。

發表論文

1 Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study.Liu L, Wang K, Yang Y, Hu M, Chen M, Liu X, Yan P, Wu N, Xiang X (通訊作者).J Clin Anesth. 2024 Feb;92:111317.

2 Prediction of Drug-Drug Interactions with Ensartinib as a Time Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model.Wang X, Yu Y, Liu H, Bu F, Shen C, He Q, Zhu X, Jiang P, Han B, Xiang X (通訊作者).Drug Metab Dispos. 2023 Nov;51(11):1515-1526

3 Yuan Y, Han Y, Yap CW, Kochhar J, Li H, Xiang X (通訊作者), Kang L. Prediction of drug permeation through microneedled skin by machine learning. Bioeng Transl Med. 2023 Apr 3;8(6):e10512

4Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function.Li A, Mak WY, Ruan T, Dong F, Zheng N, Gu M, Guo W, Zhang J, Cheng H, Ruan C, Shi Y, Zang Y, Zhu X, He Q, Xiang X, Wang G, Zhu X.Front Pharmacol. 2023 Sep 4;14:1215065.

5Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir. Yang W, Mak W, Gwee A, Gu M, Wu Y, Shi Y, He Q, Xiang X, Han B, Zhu X. Pharmaceutics. 2023;15(7):1801

6Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.Wang X, Chen F, Guo N, Gu Z, Lin H, Xiang X, Shi Y, Han B.Cancer Chemother Pharmacol. 2023 Oct;92(4):253-270.

7Evaluating the impact of co-administered drug and disease on ripretinib exposure: A physiologically-based pharmacokinetic modeling approach.Pan C, Cheng Y, He Q, Li M, Bu F, Zhu X, Li X, Xiang X (通訊作者).Chem Biol Interact. 2023;373:110400.

8 Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization.Gu M, Li A, Mak W, Dong F, Xu N, Zhang J, Shi Y, Zheng N, Tang Z, He Q, Ruan C, Guo W, Xiang X, Wang C, Han B, Zhu X.Front Pharmacol. 2023;14:1089862.

9Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model.Yuan Y, Li Z, Wang K, Zhang S, He Q, Liu L, Tang Z, Zhu X, Chen Y, Cai W, Peng C, Xiang X (通訊作者). Molecules. 2023;28(2):837.

10 Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. Ran XB, Ding LW, Sun QY, Yang H, Said JW, Zhentang L, Madan V, Dakle P, Xiao JF, Loh X, Li Y, Xu L, Xiang X, Wang LZ, Goh BC, Lin DC, Chng WJ, Tan SY, Jha S, Koeffler HP. Cancer Res. 2023 Mar 15;83(6):922-938.

11 Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling. Ji X, Meng X, He Q, Xiang X, Shi Y, Zhu X. Int J Mol Sci. 2023 Jan 1;24(1):757.

12 Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview. Jia Q, He Q, Yao L, Li M, Lin J, Tang Z, Zhu X, Xiang X (通訊作者). Molecules. 2022; 27(24):8670.

13 Applications of In Silico Models to Predict Drug-Induced Liver Injury.Lin J, Li M, Mak W, Shi Y, Zhu X, Tang Z, He Q, Xiang X (通訊作者). Toxics. 2022;10(12):788.

14 Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Feng Z, Li X, Tong WK, He Q, Zhu X, Xiang X, Tang Z. Front Pharmacol. 2022;13:894685.

15 Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib.Liu H, Yu Y, Liu L, Wang C, Guo N, Wang X, Xiang X (通訊作者), Han B.Front Pharmacol. 2022;13:970539.

16 Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.Wen HN, He QF, Xiang X (通訊作者), Jiao Z, Yu JG.Thromb Res. 2022;218:24-34.

17 Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae. Ji XW, Zhu X, Li Y, Xue F, Kuan IHS, He QF, Meng XR, Xiang X (通訊作者), Cui YM, Zheng B. Front Pharmacol. 2022 Jul 18;13:856792

18 Frailty in Community-Dwelling Adults Aged 40 Years and over with Type 2 Diabetes: Association with Self-Management Behaviors. Tang Z, Shen C, Tong W, Xiang X, Feng Z, Han B. Int J Environ Res Public Health. 2022;19(15):9092

19 Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.Jin S, Li Z, Yang Q, Fang B, Xiang X, Peng C, Cai W.Pharmaceutics. 2022 May 27;14(6):1141

20 Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs. Yuan Y, He Q, Zhang S, Li M, Tang Z, Zhu X, Jiao Z, Cai W, Xiang X (通訊作者). Front Pharmacol. 2022;13:895556.

21 Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach. He Q, Bu F, Wang Q, Li M, Lin J, Tang Z, Mak WY, Zhuang X, Zhu X, Lin HS, Xiang X (通訊作者). Int J Mol Sci. 2022;23(9):4485.

22 Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.Jin Z, He Q, Zhu X, Zhu M, Wang Y, Wu XA, Lv Q, Xiang X (通訊作者).Basic Clin Pharmacol Toxicol. 2022;130(5):592-605.

23 The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy.Li J, Zhang G, Liu CG, Xiang X, Le MTN, Sethi G, Wang L, Goh BC, Ma Z.Theranostics. 2022;12(1):87-104.

24 Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib.Liu H, Yu Y, Guo N, Wang X, Han B, Xiang X (通訊作者).Front Pharmacol. 2021;12:780937.

25 Simultaneous Quantification of Propylthiouracil and Its N-β-d Glucuronide by HPLC-MS/MS: Application to a Metabolic Study.Li M, He Q, Yao L, Wang X, Tang Z, Zhu X, Lin HS, Xiang X (通訊作者).Pharmaceuticals (Basel). 2021 Nov 20;14(11):1194. doi: 10.3390/ph14111194.

26 Systematic Study on a Quantitative Analysis of Multicomponents by Single Marker (QAMS) Method for Simultaneous Determination of Eight Constituents in Pneumonia Mixture by UPLC-MS/MS.Zhang H, Xie W, Liu J, Xiang X, Zhang S, Hu J, Yang J.J Anal Methods Chem. 2021 Nov 3;2021:8311588. doi: 10.1155/2021/8311588. eCollection 2021.

27 A Novel Method for Predicting the Human Inherent Clearance and Its Application in the Study of the Pharmacokinetics and Drug-Drug Interaction between Azidothymidine and Fluconazole Mediated by UGT Enzyme.Yuan Y, Zhang J, Fang B, Xiang X, Ma G, Zhang S, Zhu B, Cai W.Pharmaceutics. 2021;13(10):1734.

28 Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.Liu C, Xiang X(共同一作), Han S, Lim HY, Li L, Zhang X, Ma Z, Yang L, Guo S, Soo R, Ren B, Wang L, Goh BC.Cancer Lett. 2022;524:91-102.

29 Differentiation of Human Pluripotent Stem Cells Into Definitive Endoderm Cells in Various Flexible Three-Dimensional Cell Culture Systems: Possibilities and Limitations.Bogacheva MS, Harjumäki R, Flander E, Taalas A, Bystriakova MA, Yliperttula M, Xiang X (通訊作者), Leung AW, Lou YR.Front Cell Dev Biol. 2021;9:726499.

30 Celastrol in cancer therapy: Recent developments, challenges and prospects.Lim HY, Ong PS, Wang L, Goel A, Ding L, Li-Ann Wong A, Ho PC, Sethi G, Xiang X (通訊作者), Goh BC.Cancer Lett. 2021 Sep 8;521:252-267.

31 A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.Wang Z, Xiang X(共同一作), Liu S, Tang Z, Sun H, Parvez M, Ghim JL, Shin JG, Cai W.Drug Metab Pharmacokinet. 2021;39:100362.

32 Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, Xiang X, Xie P, Wu C, Kang L.Int J Pharm. 2021;606:120868.

33 Resveratrol for cancer therapy: Challenges and future perspectives.Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, Xiang X, Ho PC, Wang L, Ong PS, Goh BC.Cancer Lett. 2021;515:63-72.

34 Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?Weng J, Xiang X, Ding L, Wong AL, Zeng Q, Sethi G, Wang L, Lee SC, Goh BC.Semin Cancer Biol. 2021;74:105-120.

35 Prediction of oral hepatotoxic dose of natural products derived from Traditional Chinese medicines based on SVM classifier and PBPK modeling. Li S, Yu Y, Bian X, Yao L, Li M, Lou Y, Yuan J, Lin H, Liu L, Han B, Xiang X (通訊作者). Archives of Toxicology. 2021;95(5):1683-1701.（ESI高被引論文）

36 Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. He Q, Bu F, Zhang H, Wang Q, Tang Z, Yuan J, Lin HS, Xiang X (通訊作者).Pharmaceuticals 2021, 14, 198.

37 Simulation of the In Vivo Fate of Polymeric Nanoparticles Traced by Environment-Responsive Near-Infrared Dye: A Physiologically Based Pharmacokinetic Modelling Approach.Li L, He H, Jiang S, Qi J, Lu Y, Ding N, Lin HS, Wu W, Xiang X (通訊作者).Molecules. 2021;26(5):1271.

38 Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.Zhang M, Yao X, Hou Z, Guo X, Tu S, Lei Z, Yu Z, Liu X, Cui C, Chen X, Shen N, Song C, Qiao J, Xiang X, Li H, Liu D.Front Pharmacol. 2021;11:585021.

39 Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).Yuan J, Li M, Yu Y, Lee TY, Lv G, Han B, Xiang X (通訊作者), Lu ZK.Drugs Real World Outcomes. 2021;8(2):131-140.

40 Tiny miRNAs Play a Big Role in the Treatment of Breast Cancer Metastasis.Teo AYT, Xiang X, Le MT, Wong AL, Zeng Q, Wang L, Goh BC.Cancers (Basel). 2021;13(2):337.

41 Development, In Vitro and In Vivo Evaluation of Racecadotril Orodispersible Films for Pediatric Use. Wang B, Yang L, Wang B, Luo C, Wang Y, Wang H, Chen F, Xiang X (通訊作者). AAPS PharmSciTech. 2021;22(1):15

42 Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. Niu W, Li S, Jin S, Lin X, Zhang M, Cai W, Jiao Z, Xiang X (通訊作者).Br J Clin Pharmacol. 2021;87(7):2790-2806.

43 Validation of the Simplified Chinese Version of the Brief Diabetes Quality of Life (DQoL) Questionnaire Based on a Cross-Sectional Study.Tang Z, Jiang X, Hong L, Feng Z, He Q, Yuan J, Xiang X (通訊作者). Int J Environ Res Public Health. 2020 Nov 26;17(23):8792

44 The double-edged sword of H19 lncRNA: Insights into cancer therapy.Shermane Lim YW, Xiang X, Garg M, Le MT, Li-Ann Wong A, Wang L, Goh BC.Cancer Lett. 2021;500:253-262.

45 Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy. Ma Z, Wang LZ, Cheng JT, Lam WST, Ma X, Xiang X, Wong AL, Goh BC, Gong Q, Sethi G, Wang L.Antioxid Redox Signal. 2021;34(18):1484-1497.

46 Current Perceptions and Improvement Approaches of Pharmaceutical Care Capacity of Community Pharmacists: A Quantitative Analysis Based on Survey Data at Chinese Chain Pharmacies. Tang Z, Lhamu P, Ye H, Hong L, Xiang X (通訊作者). Int J Environ Res Public Health. 2020 ;17(20):E7482.

47 Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B-lymphoblastic leukaemia: Ma-Spore ALL 2010 study.Jiang N, Wang L, Xiang X（共同一作）, Li Z, Chiew EKH, Koo YM, Lee HS, Lin HP, Tan AM, Quah TC, Kham SKY, Goh BC, Ariffin H, Yeoh AE.Br J Clin Pharmacol. 2021 ;87(4):1990-1999.

48 Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.Zhang M, Yao X, Hou Z, Guo X, Tu S, Lei Z, Yu Z, Liu X, Cui C, Chen X, Shen N, Song C, Qiao J, Xiang X, Li H, Liu D.Front Pharmacol. 2021 Feb 12;11:585021.

49 Evaluation of the Impacts of Formulation Parameters on the Pharmacokinetics and Bioequivalence of Risperidone Orodispersible Film: a Physiologically Based Pharmacokinetic Modeling Approach. Chen F, Liu H, Wang B, Yang Z, Chen Y, Yang L, Wang B, Jiao Z, Lin HS, Quan Y, Wang H, Xiang X (通訊作者). AAPS PharmSciTech. 2020;21(7):245

50 Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. Chen Fang, Liu Hongrui, Wang Bing, Yang Liuliu, Cai Weimin, Jiao Zheng, Yang Zhou, Chen Yusheng, Quan Yingjun, Xiang X (通訊作者), Wang Hao. Frontiers in Pharmacology, 2020, 10:1692.

51 Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Cheng Cui, Miao Zhang, Xueting Yao, Siqi Tu, Zhe Hou, Valerie Sia Jie En, Xiang X, Jing Lin, Ting Cai, Ning Shen, Chunli Song, Jie Qiao, Shun Zhang, Haiyan Li, Dong-yang Liu. Acta Pharmaceutica Sinica B, 2020,10(7):1216-1227.

52 A novel strategy for prediction of human plasma protein binding using machine learning techniques. Yawen Yuan, Shuo Chang, Zheng Zhang, Zhigang Li, Size Li, Peng Xie, Wai-Ping Yau, Haishu Lin, Weimin Cai, Yanchun Zhang, Xiang X (通訊作者). Chemometrics and Intelligent Laboratory Systems, 2020, 199: 103962

53 A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.Chong QY, Kok ZH, Bui NL, Xiang X, Wong AL, Yong WP, Sethi G, Lobie PE, Wang L, Goh BC.Pharmacol Res. 2020 Jun;156:104686.

54 Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health. Dai Y, Lim JX, Yeo SCM, Xiang X, Tan KS, Fu JH, Huang L, Lin HS. Mol Nutr Food Res. 2020; 64(2):e1900905.

55 Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave’s disease: a metabolomic approach. Li X, Yang J, Jin S, Dai Y, Fan Y, Fan X, Li Z, Yang J, Yau WP, Lin H, Cai W, Xiang X (通訊作者). Archives of Toxicology. 2020;94(1):231-244.

56 An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.Wen CL, Huang K, Jiang LL, Lu XX, Dai YT, Shi MM, Tang XM, Wang QB, Zhang XD, Wang PH, Li HT, Ruan XX, Wang LW, Wang XJ, Wang Q, Lu W, Xiang X, Sun X, Xu YH, Lai LH, Zhan Q, Li HW, Peng CH, Chen J, Huang JY, Ye DY, Chen SJ, Chen Z, Li M, Fang Y, Shen BY, Zhou L.Proc Natl Acad Sci U S A. 2019 ;116(46):23264-23273.

57 A Sensitive HPLC-MS/MS Method for the Quantification of Selegiline in Beagle Dog Plasma: Application to a Pharmacokinetic Study. Liu H, Chen F, Wang B, Wang H, Jin S, Yang Z, Chen Y, Quan Y, Xiang X (通訊作者). Current Pharmaceutical Analysis. DOI : 10.2174/1573412915666190823102223

58 Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling.Li S, Yu Y, Jin Z, Dai Y, Lin H, Jiao Z, Ma G, Cai W, Han B, Xiang X (通訊作者).Biomed Pharmacother. 2019;119:109416.

59 Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury.Jin S, Li X, Fan Y, Fan X, Dai Y, Lin H, Cai W, Yang J, Xiang X(通訊作者). Basic Clin Pharmacol Toxicol. 2019;125(6):508-517.

60 Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, Yang J, Xiang X(通訊作者).Biomed Pharmacother. 2019;117:109095.

61 Establishment of rat liver microsome-hydrogel system for in vitro phase II metabolism and its application to study pharmacological effects of UGT substrates. Zhang Z, Ma G, Xue C, Sun H, Wang Z, Xiang X(通訊作者), Cai W. Drug Metab Pharmacokinet. 2019;34(2):141-147.

62 A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.Pharmaceutics. 2018;10(4):221

63 A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study.Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC. Pharmaceutics. 2018;10(3). pii: E123.

64 Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide. Xue CF, Zhang Z, Jin Y, Zhu B, Xing JF, Ma G, Xiang X, Cai WM. Acta Pharmacol Sin. 2018;39(9):1522-1532

65 Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.Dai Y, Tan ALC, Chen H, Ong PS, Xiang X, Wu J, Lin HS.J Pharm Biomed Anal. 2018;153:95-101.

66 Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, Zhuang X, Lin HS, Shin JG, Xiang X(通訊作者). Basic Clin Pharmacol Toxicol. 2018;122(3):331-340.

67 Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone. Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, Cai W, Tao T, Xiang X(通訊作者). Sci Rep. 2017 Jun 6;7(1):2829.（ESI高被引論文）

68 Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide. Tong S, Sun H, Xue C, Chen H, Liu J, Yang H, Zhou N, Xiang X(通訊作者), Cai W. Xenobiotica. 2018 Apr;48(4):368-375

69 A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling. Li J, Chai H, Li Y, Chai X, Zhao Y, Zhao Y, Tao T, Xiang X(通訊作者). PLoS One. 2016 Aug 1;11(8):e0160260.

70 Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang X, Cai WM. Acta Pharmacol Sin. 2015;36(5):614-26.

71 Application of a New Dynamic Model to Predict the In Vitro Intrinsic Clearance of Tolbutamide Using Rat Microsomes Encapsulated in a Fab Hydrogel. Zhou N, Zheng Y, Xing J, Yang H, Chen H, Xiang X, Liu J, Tong S, Zhu B, Cai W. Drug Metab Dispos. 2016;44(1):40-9.

72 Determination of naturally occurring resveratrol analog trans-4,4'-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Chen W, Yeo SC, Elhennawy MG, Xiang X, Lin HS. Anal Bioanal Chem. 2015;407(19):5793-801.

73 Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies. Ma G, Lin J, Cai W, Tan B, Xiang X, Zhang Y, Zhang P. J Pharm Biomed Anal. 2014;92:149-59.

74 Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. Xiang X, Backman JT, Neuvonen PJ, Niemi M.

Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):245-52.

75 No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M. Eur J Clin Pharmacol. 2011 Nov;67(11):1159-67.

76 High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen PJ, Niemi M. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):51-60.

77 VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Sandanaraj E, Lal S, Cheung YB, Xiang X, Kong MC, Lee LH, Ooi LL, Chowbay B. Drug Metab Pharmacokinet. 2009;24(4):365-75.

78 Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Pharmacogenet Genomics. 2009 Jun;19(6):447-57.

79 Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ, Chowbay B. Cancer Sci. 2008 Apr;99(4):816-23.

80 Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B. Pharmacogenomics. 2007 Jun;8(6):567-75.

81 Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Jada SR, Xiaochen S, Yan LY, Xiang X, Lal S, Zhou SF, Ooi LL, Chowbay B. Eur J Clin Pharmacol. 2007 Jun;63(6):555-63.

82 Pharmacogenetics of target genes across the warfarin pharmacological pathway.Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Clin Pharmacokinet. 2006;45(12):1189-200.

83 Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Xiang X, Jada SR, Li HH, Fan L, Tham LS, Wong CI, Lee SC, Lim R, Zhou QY, Goh BC, Tan EH, Chowbay B. Pharmacogenet Genomics. 2006 Sep;16(9):683-91.

84 宋麗君,劉傑, 相小強，劉麗坤，張洪亮，劉碩，陳雯，林洪生。中醫藥與酪氨酸激酶抑制劑聯合套用的精準配伍探討.現代中西醫結合雜誌,2022,31(22):3201-3206.

85 卜鳳嬌,李玲,張琇雯，孫紅，相小強，黃滔敏。重組人表皮生長因子滴眼液的處方合理性評價與分析.中國臨床藥學雜誌,2022,31(11):824-827.

86 卜鳳嬌,何慶烽,相小強，黃滔敏。口服抗新型冠狀病毒肺炎藥物奈瑪特韋/利托那韋潛在的藥動學相互作用.中國臨床藥學雜誌,2022,31(08):631-636.

87 鄧潔,蔣品,相小強，萬宏，陳春麟。蛋白降解靶向嵌合體分子的藥動學研究進展[J].中國臨床藥學雜誌,2022,31(07):554-560.

88 林嘉鎣,金冠欽,何慶烽,相小強（通訊作者）。PD-1/PD-L1抑制劑免疫相關不良反應在臨床試驗中的應對策略[J].中國臨床藥學雜誌,2022,31(04):315-320.

89 焦正,李新剛,尚德為,董婧,左笑叢,陳冰,劉劍敏,潘雁,周田彥,張菁,劉東陽,李祿金,方翼,馬廣立,丁俊傑,趙維,陳銳,相小強,王玉珠,高建軍,謝海棠,胡蓓,鄭青山.模型引導的精準用藥：中國專家共識(2021版).中國臨床藥理學與治療學,2021,26(11):1215-1228.

90 王小鳳,何慶烽,李哲,相小強（通訊作者）.生理藥動學模型套用於治療性抗體研究進展[J].中國現代套用藥學,2021,38(19):2453-2462.DOI:10.13748/j.cnki.issn1007-7693.2021.19.021.

91 沈春英,仇茂珍,顧萌,相小強,韓冰,袁靜.基於大數據的藥物警戒研究：美國食品藥品監督管理局的最新研究進展及對中國的啟示[J].藥學服務與研究,2021,21(05):389-391.

92 李敏,李思澤,姚莉,相小強（通訊作者）.數學模型預測藥源性肝損傷研究進展.中國藥理學與毒理學雜誌,2021,35(05):382-390.

93 卜鳳嬌,陳錦如,丁寧,焦正,相小強（通訊作者）.洛匹那韋/利托那韋與他汀類藥物藥動學相互作用研究進展.中國藥學雜誌,2021,56(12):957-962.

94 王曉文,何慶烽,相小強,韓冰.生理藥代動力學模型預測抑酸藥物所致藥物相互作用的研究進展。藥學學報: 2021, 56(8): 2197 −2203

95 姚莉,楊公煒,李敏,丁寧,相小強（通訊作者）。生理藥代動力學模型在藥物基因組學中的套用。中國臨床藥理學雜誌,2021,37(04):487-489.

96 姚莉,李思澤,李敏,丁寧,相小強（通訊作者）。生理藥代動力學模型在天然藥物藥動學研究中的套用。世界科學技術-中醫藥現代化,2020,22(12):4147-4153.

97 陳文君,阮鄒榮,相小強（通訊作者）。生理藥代動力學模型的發展套用動態及其與其他建模方法的融合。中國臨床藥理學與治療學,2020,25(03):299-305.

98 鄭曉潔，李思澤，袁雅文，金莎莎，李敏，相小強（通訊作者）。兒童生理藥代動力學模型及其在兒科藥物研究中的套用。藥學學報,2020,55(01):38-44.

99 王冰，劉宏銳，陳芳，全應軍，王浩，相小強（通訊作者）。口腔黏膜給藥系統的藥物動力學研究進展.藥學學報,2020,55(02):226-234.

100 劉宏銳，陳芳，相小強，全應軍，金莎莎。生理藥代動力學建模在藥劑學中的套用。中國醫藥工業雜誌，2019, 50(4)：383-391

101劉東陽，王鯤，馬廣立，相小強，劉江，趙平，陳銳，陳淵成，黃曉暉，李麗，李祿金，聶晶，王玉珠，魏春敏，盧煒，史軍，李改玲，楊進波，王亞寧，鄭青山，胡蓓。新藥研發中定量藥理學研究的價值及其一般考慮（專家共識）。中國臨床藥理學與治療學，2018, 23(9)：961-973

102金莎莎王琪珍卜鳳嬌相小強（通訊作者），腸道微生態對藥物代謝的影響。上海醫藥，2018，39（15）：22-24

103劉曉芹，蔣馨瑩，胡文清，馬國，蔡衛民，侯愛君，相小強（通訊作者）。標準化病人在臨床藥學教育中的套用。中國臨床藥學雜誌，2017，26（4）：258

104 卜鳳嬌，蔣品，張洪艷，相小強（通訊作者）。以五味子為例的多來源藥材品種鑑別研究進展。時珍國醫國藥雜誌，2015，26（11）：2734-2736

105 相小強, 陶濤, 陳慶華。透血腦屏障製劑的研究進展。中國新藥雜誌，2002;11(7):519-523.

106 范田園，魏樹禮, 相小強,等。鹽酸地爾硫卓壓制包衣脈衝片的研究。中國藥學雜誌, 2000;35(5):317-320.

著作教材

（1）《Pharmacogenomics in Precision Medicine: From a Perspective of Ethnic Differences》，主編，出版社：Springer，ISBN:978-981-15-3895-7，2020年6月12日出版

（2）《DEXTROMETHORPHAN: Pharmacology, Clinical Uses and Health Effects》，參編，Nova Science Publishers, Inc. ， 2015年第1版

（3）《臨床藥物治療學·總論》，參編，人民衛生出版社，2017年1月1日第1版，ISBN：9787117227469

（4）《藥理學》(“博學.尚醫”基礎醫學核心課程系列教材)，參編，復旦大學出版社，2016年6月1日第1版，ISBN：978-7-309-11727-1/R.1497

（5）《臨床藥學導論》，參編，科學出版社，2017年7月第1版，ISBN： 978-7-03-053001-1

（6）《小細菌大健康：現代社會慢病微生態健康管理》，副主編，復旦大學出版社; 2017年11月1日第1版

發明專利

（1）相小強，袁雅文，張政，常碩，張彥春，李治綱，蔡衛民，田凌浩。一種基於結構和等級分類的藥物蛋白結合率預測方法及系統。CN110689919B,2023-03-17授權。

（2）相小強，李敏，張政，李治綱，劉海樹，蔡衛民，田凌浩。基於結構及藥代動力學的物質結構最佳化指導方法和系統。CN110648725B,2023-06-16授權。

相小強